Maxigen Biotech (TPE:1783) Accounts Payable & Accrued Expense : NT$116.3 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Maxigen Biotech Accounts Payable & Accrued Expense?

Maxigen Biotech's quarterly accounts payable & accrued expense declined from Sep. 2023 (NT$171.0 Mil) to Dec. 2023 (NT$129.2 Mil) and declined from Dec. 2023 (NT$129.2 Mil) to Mar. 2024 (NT$116.3 Mil).

Maxigen Biotech's annual accounts payable & accrued expense increased from Dec. 2021 (NT$102.5 Mil) to Dec. 2022 (NT$147.2 Mil) but then declined from Dec. 2022 (NT$147.2 Mil) to Dec. 2023 (NT$129.2 Mil).

Maxigen Biotech Accounts Payable & Accrued Expense Historical Data

The historical data trend for Maxigen Biotech's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxigen Biotech Accounts Payable & Accrued Expense Chart

Maxigen Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

95.82

80.27

102.46

147.19

129.21

Maxigen Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															144.72	190.66	171.01	129.21	116.29

Maxigen Biotech Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Maxigen Biotech (TPE:1783) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Maxigen Biotech Inc (TPE:1783) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88, Keji 1st Rd, Guishan District, Taoyuan City, TWN, 333

Website

https://www.mbi.com.tw

Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is primarily engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products.

Maxigen Biotech (TPE:1783) Headlines

No Headlines